Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies

Addiction

Volumn 106, Issue 1, 2011, Pages 32-51

  Degenhardt, Louisa ^a,b   Bucello, Chiara ^a   Mathers, Bradley ^a   Briegleb, Christina ^a   Ali, Hammad ^a   Hickman, Matt ^c   McLaren, Jennifer ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cohort; Dependence; Heroin; Mortality; Opioid; Review

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ADULT; ASIA; AUSTRALIA AND NEW ZEALAND; CAUSE OF DEATH; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTOXICATION; MALE; META ANALYSIS; MORTALITY; NORTH AMERICA; OPIATE ADDICTION; RECURRENT DISEASE; REVIEW; SUBSTANCE ABUSE; TIME;

ADULT; ANALGESICS, OPIOID; ASIA; AUSTRALASIA; CAUSE OF DEATH; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; MALE; NORTH AMERICA; OPIOID-RELATED DISORDERS; OVERDOSE; RECURRENCE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; YOUNG ADULT;

EID: 78650013237     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03140.x     Document Type: Article

References (85)

1. United Nations Office on Drugs and Crime. World Drug Report 2008. Vienna: United Nations; 2008.
2. Degenhardt L., Larance B., Mathers B., Azim T., Kamarulzaman A., Mattick R. P. etal. Benefits and Risks of Pharmaceutical Opioids: Essential Treatment and Diverted Medication. A Global Review of Availability, Extra-Medical Use, Injection and the Association with HIV. Sydney: University of New South Wales; 2008. Available from (archived by Webcite at; 26 October 2010).
3. Goldstein A., Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 1995; 40: 139-50.
4. Hser Y. I., Hoffman V., Grella C. E., Anglin M. D. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58: 503-8.
5. Oppenheimer E., Tobutt C., Taylor C., Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299-308.
6. Hser Y.-I. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis 2007; 26: 51-60.
7. Termorshuizen F., Krol A., Prins M., Van Ameijden E. J. C. Long-term outcome of chronic drug use the Amsterdam cohort study among drug users. Am J Epidemiol 2005; 161: 271-9.
8. Gerstein D. R., Harwood H. Treating Drug Problems. Volume 1: A Study of Effectiveness and Financing of Public and Private Drug Treatment Systems. Washington, DC: National Academy Press; 1990.
9. Maddux J., Desmond D. Methadone maintenance and recovery from opioid dependence. Am J Drug Alcohol Abuse 1992; 18: 63-74.
10. Ball J., Shaffer J., Nurco D. The day-to-day criminality of heroin addicts in Baltimore-a study in the continuity of offence rates. Drug Alcohol Depend 1983; 12: 119-42.
11. Degenhardt L., Hall W., Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS (Review) (110 references). Sex Transm Infect 2006; 82: 56-63.
12. Degenhardt L., Hall W., Lynskey M., Warner-Smith M. Chapter 13. Illicit drug use. In: Ezzati M., Lopez A. D., Rodgers A., Murray R., editors. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization; 2004, p. 1109-76.
13. Hulse G., English D., Milne E., Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94: 221-30.
14. Degenhardt L., McLaren J., Ali H., Briegleb C. Methods Used in a Systematic Review of Mortality Among Dependent Users of Heroin and other Opioids. Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group: Illicit drugs discussion paper No. 9. Sydney: NDARC, University of New South Wales; 2008 [This report is available as supporting information to accompany this review. Please see details at the end of this reference list.
15. Stroup D. F., Berlin J. A., Morton S. C., Olkin I., Williamson G. D., Rennie D. etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 293: 2008-12.
16. Calabria B., Phillips B., Singleton J., Mathers B., Congreve E., Degenhardt D. etal. Searching the Grey Literature to Access Information on Drug and Alcohol Research-A Resource to Identify Drug Related Databases and Websites. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2008.
17. Vandenbroucke J. P., Von Elm E., Altman D. G., Gøtzsche P. C., Mulrow C. D., Pocock S. J. etal. Strengthening the reporting of observational studies in epidemiology (strobe): explanation and elaboration. PLOS Med 2007; 4: 1628-54.
18. Von Elm E., Altman D. G., Egger M., Pocock S. J., Gøtzsche P. C., Vandenbroucke J. P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.
19. Mohler D. M., Schulz K. F., Altman D. G., for the CONSORT Group. The CONSORT statement: revisisted recomendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4.
20. StataCorp. Stata V9.2. Texas, USA: College Station; 2007.
21. Der Simonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
22. Sharp S., Sterne J. Meta-analysis. Stata Tech Bull 1997; 38: 9-14.
23. Sharp S., Sterne J. Meta-analysis regression. Stata Tech Bull 1998; 42: 16-24.
24. Thompson S., Sharp S. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
25. World Bank. Economics List. The World Bank Group; 2009 (Accessed on September 15th 2010; archived by Webcite at).
26. Charlson F., Degenhardt L., McLaren J., Hall W., Lynskey M. Benzodiazepine related mortality. Pharmacoepidemiol Drug Saf 2009; 18(2): 93-103.
27. Nelson P., McLaren J., Degenhardt L., Bucello C., Calabria B., Roberts A. etal. What do we know about the extent of heroin and other opioid use and dependence? Results of a global systematic review. NDARC Technical Report No. 309. Sydney: National Drug and Alcohol Research Centre, University of NSW; 2010. Available at: (accessed 26 October 2010; archived by Webcite at).
28. Ghodse H., Oyefeso A., Kilpatrick B. Mortality of drug addicts in the United Kingdom 1967-1993. Int J Epidemiol 1998; 27: 473-8.
29. Eskild A., Magnus P., Samuelsen S. O., Sohlberg C., Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993; 22: 315-20.
30. Odegard E., Amundsen E. J., Kielland K. B. Fatal overdoses and deaths by other causes in a cohort of Norwegian drug abusers-a competing risk approach. Drug Alcohol Depend 2007; 89: 176-82.
31. Degenhardt L., Randall D., Hall W., Law M., Butler T., Burns L. Mortality among clients of a State-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009; 105: 9-15.
32. Randall D., Roxburgh A., Gibson A., Degenhardt L. Mortality Among People Who Use Illicit Drugs: A Toolkit for Classifying Major Causes of Death. NDARC Technical Report no. 301. Sydney: National Drug and Alcohol Research Centre, University of NSW; 2009. Available at: (accessed 26 October 2010; archived by Webcite at).
33. Zhang C., Rexrode K., Van Dam R., Li T., Hu F. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality. Sixteen years of follow-up in US women. Circulation 2008; 117: 1658-67.
34. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007; 64: 1123-31.
35. Lenton S., Dietze P., Degenhardt L., Butler T., Darke S. Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia (Editorial). Drug Alcohol Rev 2009; 28: 583-5.
36. Lenton S., Dietze P., Degenhardt L., Butler T., Darke S. Renewed call for distribution of naloxone hydrochloride for peer administration to reduce heroin-related overdoses in Australia (Letter). Med J Aust 2009; 191: 469.
37. Murray C., Lopez A. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
38. Zhang L., Ruan Y. H., Jiang Z. Q., Yang Z. N., Liu S. Z., Zhou F. etal. A 1-year prospective cohort study on mortality of injecting drug users. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih/Chin J Epidemiol 2005; 26: 190-3.
39. Azim T., Chowdhury E., Reza M., Faruque M. O., Ahmed G., Khan R. etal. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. Subst Use Misuse 2008; 43: 2124-44.
40. Azim T., Khan S. I., Nahar Q., Reza M., Alam N., Saifi R. etal. 20 Years of HIV in Bangladesh: Experiences and Way Forward. 2009. Daka: World Bank.
41. Quan V. M., Vongchak T., Jittiwutikarn J., Kawichai S., Srirak N., Wiboonnatakul K. etal. Predictors of mortality among injecting and non-injecting HIV-negative drug users in northern Thailand. Addiction 2007; 102: 441-6.
42. Bartu A. Bartu etal. (2004): a correction. Addiction 2006; 101: 1524.
43. Bartu A., Freeman N. C., Gawthorne G. S., Codde J. P., Holman C. Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction 2004; 99: 53-60.
44. Digiusto E., Shakeshaft A., Ritter A., O'Brien S., Mattick R. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004; 99: 450-60.
45. Digiusto E., Shakeshaft A., Ritter A., O'Brien S., Mattick R. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD): corrigendum. Addiction 2005; 100: 450-60.
46. Tait R. J. N., Hanh T., Hulse T., Kenneth G. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008; 35: 116-24.
47. Lejckova P., Mravcik V. Mortality of hospitalized drug users in the Czech Republic. J Drug Issues 2007; 37: 103-18.
48. Moskalewicz J., Sieroslawski J. Mortality of narcotic addicts using injections. Przegl Epidemiol 1996; 50: 323-32.
49. Risser D., Hönigschnabl S., Stichenwirth M., Pfudl S., Sebald D., Kaff A. etal. Mortality of opiate users in Vienna, Austria. Drug Alcohol Depend 2001; 64: 251-6.
50. Bargagli A. M., Hickman M., Davoli M., Perucci C. A., Schifano P., Buster M. etal. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006; 16: 198-202.
51. Bauer S. M., Loipl R., Jagsch R., Gruber D., Risser D., Thau K. etal. Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res 2008; 14: 82-91.
52. Sorensen H., Jepsen P. W., Haastrup S., Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005; 111: 244-9.
53. Observatoire Français des Drogues et des Toxicomanies (OFDT). Mortality of individuals arrested for heroine, cocaine or crack use (French Monitoring Centre for Drugs and Drug Addiction). 2004. Paris France: Observatoire Français des Drogues et des Toxicomanies.
54. Marzo J.-N., Rotily M., Meroueh F., Varastet M., Hunault C., Zin A. (2008) Readmissions and mortality among imprisoned opiate addicts: A prospective cohort study (2003-2006). Paris: Observatoire Français des Drogues et des Toxicomanies, OFDT (Saint-Denis).
55. Soyka M., Apelt S. M., Lieb M., Wittchen H.-U. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006; 26: 657-60.
56. Scherbaum N., Specka M., Hauptmann G., Gastpar M. Does maintenance treatment reduce the mortality rate of opioid addicts? Fortschr Neurol Psychiatr 2002; 70: 455-61.
57. Smyth B. P., Barry J., Lane A., Cotter M., O'Neill M., Quinn C. etal. In-patient treatment of opiate dependence: medium-term follow-up outcomes (see Comment). Br J Psychiatry 2005; 187: 360-5.
58. Antolini G., Pirani M., Morandi G., Sorio C. Gender difference and mortality in a cohort of heroin users in the Provinces of Modena and Ferrara, 1975-1999. Epidemiol Prev 2006; 30: 91-9.
59. Brancato V., Delvecchio G., Simone P. Survival and mortality in a cohort of heroin addicts in 1985-1994. Minerva Med 1995; 86: 97-9.
60. Manfredi R., Sabbatani S., Agostini D. Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. Coll Antropol 2006; 30: 479-88.
61. Galli M., Musicco M. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. COMCAT Study Group. AIDS 1994; 8: 1457-63.
62. Bargagli A. M., Sperati A., Davoli M., Forastiere F., Perucci C. Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97. Addiction 2001; 96: 1455-63.
63. Goedert J. J., Pizza G., Gritti F. M., Costigliola P., Boschini A., Bini A. etal. Mortality among drug users in the AIDS era. Int J Epidemiol 1995; 24: 1204-10.
64. Ferri M., Bargagli A. M., Faggiano F., Belleudi V., Salamina G., Vigna-Taglianti F. etal. Mortality of drug users attending public treatment centres in Italy 1998-2001: a cohort study. Epidemiol Prev 2007; 31: 276-82.
65. Langendam M. W., Van Brussel G. H., Coutinho R. A., Van Ameijden E. J. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001; 91: 774-80.
66. Buster M. C., Van Brussel G. H., Van Den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002; 97: 993-1001.
67. Rossow I. Suicide among drug addicts in Norway. Addiction 1994; 89: 1667-73.
68. Clausen T., Anchersen K., Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94: 151-7.
69. Haarr D., Nessa J. Treatment of opiate-dependent patients in a general practice.(see comment). Tidsskr Nor Laegeforen 2007; 127: 1770-2.
70. Ortí R. M., Domingo-Salvany A., Muñoz A., Macfarlane D., Suelves J. M., Antó J. M. Mortality trends in a cohort of opiate addicts, Catalonia, Spain. Int J Epidemiol 1996; 25: 545-53.
71. Sanchez-Carbonell X., Seus L. Ten-year survival analysis of a cohort of heroin addicts in Catalonia: the EMETYST project. Addiction 2000; 95: 941-8.
72. Esteban J., Gimeno C., Barril J., Aragonés A., Climent J. M., De La Cruz Pellín M. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend 2003; 70: 193-200.
73. Muga R., Langohr K., Tor J., Sanvisens A., Serra I., Rey-Joly C. etal. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 2007; 45: 370-6.
74. Stenbacka M., Leifman A., Romelsjo A. Mortality among opiate abusers in Stockholm: a longitudinal study. Heroin Addict Relat Clin Probl 2007; 9: 41-9.
75. Wahren C. A., Brandt L., Allebeck P. Has mortality in drug addicts increased? A comparison between two hospitalized cohorts in Stockholm. Int J Epidemiol 1997; 26: 1219-26.
76. Fugelstad A., Annell A., Rajs J., Agren G. Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981-1992. Acta Psychiatr Scand 1997; 96: 169-75.
77. Fugelstad A., Agren G., Romelsjo A. Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment. Subst Use Misuse 1998; 33: 2803-17.
78. Fridell M., Hesse M. Psychiatric severity and mortality in substance abusers: a 15-year follow-up of drug users. Addict Behav 2006; 31: 559-65.
79. Seaman S. R., Brettle R. P., Gore S. M. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 1998; 316: 426-8.
80. Miller C. L., Kerr T., Strathdee S. A., Li K., Wood E. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J 2007.
81. Price R. K., Risk N. K., Murray K. S., Virgo K. S., Spitznagel E. L. Twenty-five year mortality of US servicemen deployed in Vietnam: predictive utility of early drug use. Drug Alcohol Depend 2001; 64: 309-18.
82. Vlahov D., Wang C., Ompad D., Fuller C. M., Caceres W., Ouellet L. etal. Mortality risk among recent-onset injection drug users in five U.S. cities. Subst Use Misuse 2008; 43: 413-28.
83. Wang C., Vlahov D., Galai N., Cole S. R., Bareta J., Pollini R. etal. The effect of HIV infection on overdose mortality. Aids 2005; 19: 935-42.
84. Vlahov D., Galai N., Safaeian M., Galea S., Kirk G. D., Lucas G. M. etal. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005; 161: 999-1012.
85. Vlahov D., Wang C. L., Galai N., Bareta J., Mehta S. H., Strathdee S. A. etal. Mortality risk among new onset injection drug users. Addiction 2004; 99: 946-54.